Cancer vaccines containing autologous monocyte-derived mature DCs conventionally manufactured using granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-4 are principally targeted against a specific antigen. This evidence concerns the gene CSF2 and cancer.